{"id":"https://openalex.org/W2986668065","doi":"https://doi.org/10.1182/blood-2019-121936","title":"Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia","display_name":"Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia","publication_year":2019,"publication_date":"2019-11-13","ids":{"openalex":"https://openalex.org/W2986668065","doi":"https://doi.org/10.1182/blood-2019-121936","mag":"2986668065"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2019-121936","doi":"https://doi.org/10.1182/blood-2019-121936","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-121936","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015361329","display_name":"Nina D. Wagner\u2010Johnston","orcid":"https://orcid.org/0000-0001-6529-9793","observed_orcids":["https://orcid.org/0000-0001-6529-9793"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]},{"id":"https://openalex.org/I4210150714","display_name":"Johns Hopkins Hospital","ror":"https://ror.org/05cb1k848","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210150714"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nina D. Wagner-Johnston","raw_affiliation_strings":["Johns Hopkins Hospital, Baltimore, MD","Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johns Hopkins Hospital, Baltimore, MD","institution_ids":["https://openalex.org/I4210150714"]},{"raw_affiliation_string":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD","institution_ids":["https://openalex.org/I145311948","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080630441","display_name":"Stephen J. Schuster","orcid":"https://orcid.org/0000-0002-3376-8978","observed_orcids":["https://orcid.org/0000-0002-3376-8978"]},"institutions":[{"id":"https://openalex.org/I4390039297","display_name":"Abramson Cancer Center","ror":"https://ror.org/01hvpjq66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210143392","https://openalex.org/I4390039297"]},{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen J. Schuster","raw_affiliation_strings":["Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I4390039297","https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081213752","display_name":"Sven de Vos","orcid":"https://orcid.org/0000-0002-6715-4851","observed_orcids":["https://orcid.org/0000-0002-6715-4851"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sven de Vos","raw_affiliation_strings":["David Geffen School of Medicine at UCLA, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine at UCLA, Los Angeles, CA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086354986","display_name":"Gilles A. Salles","orcid":"https://orcid.org/0000-0002-9541-8666","observed_orcids":["https://orcid.org/0000-0002-9541-8666"]},"institutions":[{"id":"https://openalex.org/I4210100596","display_name":"Hospices Civils de Lyon","ror":"https://ror.org/01502ca60","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210100596"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles A. Salles","raw_affiliation_strings":["Hospices Civils de Lyon, Universit\u00e9 Claude Bernard, Lyon, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospices Civils de Lyon, Universit\u00e9 Claude Bernard, Lyon, France","institution_ids":["https://openalex.org/I4210100596"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788725","display_name":"Wojciech J. Jurczak","orcid":"https://orcid.org/0000-0003-1879-8084","observed_orcids":["https://orcid.org/0000-0003-1879-8084"]},"institutions":[{"id":"https://openalex.org/I126596746","display_name":"Jagiellonian University","ror":"https://ror.org/03bqmcz70","country_code":"PL","type":"education","lineage":["https://openalex.org/I126596746"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Wojciech Jurczak","raw_affiliation_strings":["Jagiellonian University, Krakow, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jagiellonian University, Krakow, Poland","institution_ids":["https://openalex.org/I126596746"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024466353","display_name":"Nishan Rajakumaraswamy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nishan Rajakumaraswamy","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081758381","display_name":"Guan Xing","orcid":"https://orcid.org/0000-0001-6011-3267","observed_orcids":["https://orcid.org/0000-0001-6011-3267"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guan Xing","raw_affiliation_strings":["Gilead Sciences, Inc., Foster City, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gilead Sciences, Inc., Foster City, CA","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I1332479046","display_name":"Seattle Cancer Care Alliance","ror":"https://ror.org/03jq88n71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1332479046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":["Seattle Cancer Care Alliance, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seattle Cancer Care Alliance, Seattle, WA","institution_ids":["https://openalex.org/I1332479046"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"134","issue":"Supplement_1","first_page":"4006","last_page":"4006"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.7031000256538391,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.7031000256538391,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.2946999967098236,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11811","display_name":"Cutaneous lymphoproliferative disorders research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/idelalisib","display_name":"idelalisib","score":0.9819999933242798},{"id":"https://openalex.org/keywords/marginal-zone-lymphoma","display_name":"marginal zone lymphoma","score":0.878000020980835},{"id":"https://openalex.org/keywords/lymphoplasmacytic-lymphoma","display_name":"lymphoplasmacytic lymphoma","score":0.968999981880188},{"id":"https://openalex.org/keywords/waldenstrom-macroglobulinemia","display_name":"Waldenstr\u00f6m macroglobulinemia","score":0.968999981880188},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.9259999990463257},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.8659999966621399},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7879999876022339},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8960000276565552},{"id":"https://openalex.org/keywords/ibrutinib","display_name":"ibrutinib","score":0.5789999961853027}],"concepts":[{"id":"https://openalex.org/C2910423619","wikidata":"https://www.wikidata.org/wiki/Q1778287","display_name":"Lymphoplasmacytic Lymphoma","level":4,"score":0.8725361824035645},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7794320583343506},{"id":"https://openalex.org/C2781038049","wikidata":"https://www.wikidata.org/wiki/Q1778287","display_name":"Waldenstrom macroglobulinemia","level":3,"score":0.7489581108093262},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.7198975086212158},{"id":"https://openalex.org/C2779260929","wikidata":"https://www.wikidata.org/wiki/Q5908266","display_name":"Idelalisib","level":5,"score":0.6646744012832642},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6437204480171204},{"id":"https://openalex.org/C2776391228","wikidata":"https://www.wikidata.org/wiki/Q4118092","display_name":"Macroglobulinemia","level":3,"score":0.6304900646209717},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5758705735206604},{"id":"https://openalex.org/C2779380147","wikidata":"https://www.wikidata.org/wiki/Q3832900","display_name":"Splenic marginal zone lymphoma","level":4,"score":0.5468156337738037},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4617356061935425},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.44105058908462524},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3919390141963959},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.19895589351654053},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.1810021996498108},{"id":"https://openalex.org/C2776309230","wikidata":"https://www.wikidata.org/wiki/Q580383","display_name":"Splenectomy","level":3,"score":0.14297956228256226},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.08757051825523376},{"id":"https://openalex.org/C2780931953","wikidata":"https://www.wikidata.org/wiki/Q9371","display_name":"Spleen","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2019-121936","doi":"https://doi.org/10.1182/blood-2019-121936","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2019-121936","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2522786622","https://openalex.org/W3113119624","https://openalex.org/W2175253063","https://openalex.org/W2468328813","https://openalex.org/W4230754783","https://openalex.org/W2244500181","https://openalex.org/W2397507813","https://openalex.org/W4405048706","https://openalex.org/W3212937025","https://openalex.org/W3168639167"],"abstract_inverted_index":{"Introduction:":[0],"Marginal":[1],"zone":[2,1138],"lymphoma":[3,7,161,1081,1113,1139],"(MZL)":[4],"and":[5,14,95,126,139,145,223,255,265,273,284,305,348,353,378,411,422,463,499,509,536,560,594,635,659,667,752,1009,1022,1043,1070,1109,1140],"lymphoplasmacytic":[6,1141],"(LPL)/Waldenstrom's":[8],"macroglobulinemia":[9],"(WM)":[10],"comprise":[11],"approximately":[12],"7%":[13],"2%,":[15],"respectively,":[16],"of":[17,85,101,155,160,165,167,212,282,286,318,334,396,398,445,448,486,488,648,655,696,707,718,730,750,802,823,846,859,880,895,909,925,964,977,1054,1078,1128,1133],"non-Hodgkin's":[18],"lymphomas":[19,1066],"(NHL)":[20],"(Teras":[21],"2016).":[22],"MZL":[23,29,32,36,61,94,125,242,283,304,347,658],"is":[24,1049,1074],"further":[25],"subclassified":[26],"as":[27,153],"splenic":[28],"(sMZL),":[30],"nodal":[31],"(nMZL),":[33],"or":[34,52,158,185,623,698,709,720,732,804,825,848,861,882,897,911,927,966,979],"extranodal":[35],"(eMZL).":[37],"Standard":[38],"first-line":[39,58,78],"therapies":[40],"for":[41,60,72,121,301,316,332,363,574,676,1076],"LPL/WM":[42,127,287,308,319,336,349,660,677],"include":[43],"rituximab":[44,144,372,666,1097,1099],"plus":[45],"an":[46,146,191,668,693,704,715,727,799,820,843,856,877,892,906,922,961,974],"alkylating":[47,147,669],"agent":[48],"and/or":[49],"proteasome":[50],"inhibitor":[51,84,1053],"ibrutinib":[53],"(Castillo":[54],"2017),":[55],"while":[56],"standard":[57,196],"treatment":[59,70,606,1077],"varies":[62],"by":[63,171,190],"subtype":[64],"(Rosand":[65],"2017).":[66],"There":[67,505],"are":[68],"limited":[69],"options":[71],"patients":[73,122,135,237,288,320,337,366,430,514,547,603,628,656],"who":[74],"have":[75,629],"relapsed":[76,1079,1090,1110],"after":[77],"therapy.":[79],"Idelalisib,":[80],"a":[81,98,106,408,483,502,557,568,1050],"selective":[82,1051],"oral":[83,1052],"PI3K\u03b4,":[86],"demonstrated":[87],"efficacy":[88],"in":[89,105,433,442,525,651,1061,1067,1094],"indolent":[90,1064,1134],"NHL":[91],"(iNHL),":[92],"including":[93],"LPL/WM,":[96,473],"at":[97,296],"median":[99,311,394,464,484,537],"follow-up":[100],"9.7":[102],"months":[103],"(mos)":[104],"phase":[107,1068,1147],"2":[108,1071,1086,1118,1129,1148],"study":[109,634],"(NCT01282424;":[110],"101-09;":[111],"Gopal":[112],"2014).":[113],"Here,":[114],"we":[115,1125],"present":[116],"the":[117,129,383,443,446,449,474,599,633,638,1145],"final,":[118],"long-term":[119,639,1151],"results":[120,1127],"with":[123,338,393,436,482,519,643,657,665,755,1096,1150],"double-refractory":[124],"from":[128],"101-09":[130],"study.":[131],"Methods:":[132],"Eligible":[133],"iNHL":[134],"had":[136,241,258,289,356,407,413,418,424,431,497,501,515,548,556,563],"measurable":[137],"disease":[138,183,420,426,609,672],"were":[140,188,267,598,683],"refractory":[141,661],"to":[142,157,209,567,608,662,758,1106],"both":[143],"agent.":[148],"Refractory":[149],"status":[150],"was":[151,179,230,262,298,314,329,389,456,466,478,506,529,539,674],"defined":[152],"lack":[154],"response":[156,205,213,410],"progression":[159,184,610],"within":[162],"6":[163,412],"mos":[164,462,470,535,543],"completion":[166],"preceding":[168],"therapy,":[169],"documented":[170],"imaging.":[172],"Oral":[173],"idelalisib":[174,644],"150":[175],"mg":[176],"twice":[177],"daily":[178],"administered":[180],"continuously":[181],"until":[182],"intolerance.":[186],"Responses":[187],"evaluated":[189],"independent":[192],"review":[193],"committee":[194],"using":[195],"criteria":[197],"(Cheson":[198],"2007;":[199],"Owen":[200],"2013).":[201],"Endpoints":[202],"included":[203,367],"overall":[204,221],"rate":[206],"(ORR),":[207],"time":[208],"response,":[210,217],"duration":[211,395,485],"(DOR),":[214],"lymph":[215,434,516],"node":[216,517],"progression-free":[218],"survival":[219],"(PFS),":[220],"survival,":[222],"safety.":[224],"The":[225,293],"final":[226],"data":[227],"cutoff":[228],"date":[229],"22":[231,530,575],"Oct":[232],"2018.":[233],"Results:":[234],"Of":[235,403,493],"125":[236],"enrolled,":[238],"15":[239],"(12%)":[240],"(sMZL,":[243],"n":[244,248,252],"=":[245,249,253,270,276,580],"1;":[246],"nMZL,":[247],"5;":[250],"eMZL,":[251],"9)":[254],"10":[256],"(8.0%)":[257],"LPL/WM.":[259],"Median":[260,454,527],"age":[261],"65":[263],"years":[264],"most":[266,600],"non-Hispanic":[268],"(n":[269,275,579],"24;":[271],"96%)":[272],"White":[274],"23;":[277],"92%).":[278],"At":[279],"diagnosis,":[280],"80%":[281,317,479],"100%":[285],"stage":[290],"IV":[291],"disease.":[292],"largest":[294],"lesion":[295],"baseline":[297],"\u22655":[299],"cm":[300],"5":[302,520],"(33%)":[303],"3":[306,631],"(30%)":[307],"patients.":[309,678],"Baseline":[310,326],"IgM":[312],"level":[313,328],"elevated":[315],"(median":[321,341],"1.9,":[322],"IQR":[323],"1.0-2.7":[324],"g/dL).":[325],"beta2-microglobulin":[327],">3":[330],"\u00b5g/mL":[331],"1":[333,406,423,500,507,510,1069],"9":[335],"values":[339],"recorded":[340],"2.5":[342],"[range":[343],"1.7-3.1]":[344],"\u00b5g/mL).":[345],"For":[346,381,472],"patients,":[350],"7":[351,354,404,496,636],"(47%)":[352],"(70%)":[355],"\u22653":[357,571],"prior":[358,663,1087,1119],"therapies,":[359,1089],"respectively.":[360],"Common":[361],"regimens":[362],"all":[364],"25":[365,546],"rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone":[368],"(44%),":[369],"rituximab-cyclophosphamide-vincristine-prednisone":[370],"(40%),":[371],"only":[373,376],"(28%),":[374],"bendamustine":[375],"(24%),":[377],"bendamustine-rituximab":[379],"(20%).":[380],"MZL,":[382],"ORR":[384,475],"(95%":[385,458,476,531],"confidence":[386],"interval":[387],"[CI])":[388],"47%":[390],"(21%,":[391],"73%),":[392],"therapy":[397,487,664],"6.4":[399],"(range":[400,468,490,541],"1.8-37)":[401],"mos.":[402,492],"responders,":[405,495],"complete":[409],"partial":[414],"responses":[415],"(PR).":[416],"Seven":[417],"stable":[419],"(SD)":[421],"progressive":[425],"(PD).":[427],"Fourteen":[428],"(93%)":[429],"reduction":[432,441,524],"nodes,":[435],"8":[437,494],"(53%)":[438],"having":[439,522],"\u226550%":[440,523],"sum":[444],"products":[447],"greatest":[450],"perpendicular":[451],"diameters":[452],"(SPD).":[453],"PFS":[455,528],"6.6":[457],"CI":[459,532],"3.5,":[460],"22)":[461],"DOR":[465,538],"18":[467],"0-18)":[469],"(Table).":[471,544],"CI)":[477],"(44%,":[480],"98%),":[481],"29":[489],"6.4-51)":[491],"PR":[498],"minor":[503],"response.":[504],"SD":[508],"PD.":[511],"Nine":[512],"(90%)":[513],"reduction,":[518],"(50%)":[521],"SPD.":[526],"1.4,":[533],"56)":[534],"20":[540],"1.7-50)":[542],"All":[545,602],"\u22651":[549],"treatment-emergent":[550],"adverse":[551],"event":[552],"(TEAE),":[553],"16":[554],"(64%)":[555],"serious":[558],"AE,":[559],"11":[561],"(44%)":[562],"dose":[564],"reduced":[565],"due":[566,607,1105],"TEAE.":[569],"Grade":[570],"TEAEs":[572],"occurred":[573],"(88%)":[576],"patients;":[577],"neutropenia":[578],"7,":[581],"28%),":[582,585],"diarrhea":[583],"(7,":[584],"alanine":[586],"aminotransferase":[587],"increased":[588],"(4,":[589],"16%),":[590],"asthenia":[591],"(3,":[592,596,617],"12%),":[593,618],"pneumonia":[595],"12%)":[597],"frequent.":[601],"eventually":[604],"discontinued":[605],"(14,":[611],"56%),":[612],"AE":[613],"(6,":[614],"24%),":[615],"death":[616],"investigator":[619],"request":[620],"(1,":[621,625],"4%),":[622],"other":[624,1107],"4%).":[626],"Ten":[627],"died,":[630],"during":[632,637],"follow-up.":[640,687,1152],"Conclusions:":[641],"Monotherapy":[642],"showed":[645],"high":[646],"rates":[647],"antitumor":[649,1059],"activity":[650,1060],"this":[652,1123],"small":[653,1111],"subset":[654],"agent;":[670],"prolonged":[671],"control":[673],"achieved":[675],"No":[679],"new":[680],"safety":[681],"signals":[682],"identified":[684],"despite":[685],"longer":[686],"Disclosures":[688],"Wagner-Johnston:":[689],"Bayer:":[690,807],"Membership":[691,702,713,725,797,818,841,854,875,890,904,920,959,972],"on":[692,703,714,726,798,819,842,855,876,891,905,921,960,973,1085,1117],"entity's":[694,705,716,728,800,821,844,857,878,893,907,923,962,975],"Board":[695,706,717,729,801,822,845,858,879,894,908,924,963,976],"Directors":[697,708,719,731,803,824,847,860,881,896,910,926,965,978],"advisory":[699,710,721,733,805,826,849,862,883,898,912,928,967,980],"committees;":[700,711,722,806,850],"Jannsen:":[701],"Gilead:":[712,788,942],"ADC":[723],"Therapeutics:":[724,955],"committees.":[734,899],"Schuster:Genentech:":[735],"Honoraria,":[736,740,744,765,769,773,785,789,817,832,840,853,874],"Research":[737,741,760,766,770,774,786,790,901,914,917,930,934,937,940,943,946,949,952,956,969,982,1024],"Funding;":[738,742,761,767,771,775,787,902,915,918,931,935,938,941,944,947,950,953,957,970,1025],"Celgene:":[739,815],"Novartis:":[743],"Patents":[745],"&":[746],"Royalties:":[747],"Combination":[748],"Therapies":[749],"CAR":[751],"PD-1":[753],"Inhibitors":[754],"royalties":[756],"paid":[757],"Novartis,":[759,867],"AstraZeneca:":[762,903],"Honoraria;":[763,778,781,783,811,837],"Pharmacyclics:":[764],"Merck:":[768,838],"Acerta:":[772],"Loxo":[776],"Oncology:":[777],"Nordic":[779],"Nanovector:":[780],"Pfizer:":[782],"AbbVie:":[784],"Funding.":[791,983],"de":[792],"Vos:Verastem:":[793],"Consultancy;":[794,1011],"Portola":[795],"Pharmaceuticals:":[796],"Consultancy.":[808],"Salles:Epizyme:":[809],"Consultancy,":[810,816,839,852,873,889],"Roche,":[812],"Janssen,":[813,995,1020,1029],"Gilead,":[814,996,1030],"committees,":[827,863,884,913,929,968,981],"Other:":[828,833,864,885],"Educational":[829,834,865,886],"events;":[830,835,866,887],"Amgen:":[831],"BMS:":[836],"Takeda:":[851,951],"Servier,":[868],"AbbVie,":[869],"Karyopharm,":[870],"Kite,":[871],"MorphoSys:":[872,939],"Autolus:":[888],"Jurczak:Bayer:":[900],"Incyte:":[916,1044],"Sandoz:":[919],"Novo":[932],"Nordisk:":[933],"Celtrion:":[936],"Roche:":[945],"Servier:":[948],"TG":[954],"Loxo:":[958],"Janssen:":[971],"Rajakumaraswamy:Gilead":[984],"Sciences,":[985,989],"Inc.:":[986,990],"Employment.":[987,991],"Xing:Gilead":[988],"Gopal:Seattle":[992],"Genetics,":[993,1018,1027],"Pfizer,":[994,1019,1028],"Sanofi,":[997,1031],"Spectrum,":[998,1032],"Amgen,":[999,1033],"Aptevo,":[1000,1034],"BRIM":[1001,1035],"bio,":[1002,1036],"Acerta,":[1003,1037],"I-Mab-pharma,":[1004,1038],"Takeda,":[1005,1016,1021,1039],"Compliment,":[1006,1040],"Asana":[1007,1041],"Bio,":[1008,1042],"Incyte.:":[1010],"Teva,":[1012],"Bristol-Myers":[1013],"Squibb,":[1014],"Merck,":[1015],"Seattle":[1017,1026],"Effector:":[1023],"Honoraria.":[1045],"OffLabel":[1046],"Disclosure:":[1047],"Idelalisib":[1048],"PI3K-delta":[1055],"that":[1056,1082,1114],"has":[1057,1083,1115],"shown":[1058],"previously":[1062],"treated":[1063],"non-Hodgkins":[1065,1135],"studies.":[1072],"It":[1073],"approved":[1075],"follicular":[1080],"progressed":[1084,1116],"systemic":[1088,1120],"chronic":[1091],"lymphocytic":[1092,1112],"leukemia":[1093],"combination":[1095],"when":[1098],"alone":[1100],"would":[1101],"be":[1102],"considered":[1103],"appropriate":[1104],"comorbidities,":[1108],"therapies.":[1121],"In":[1122],"presentation,":[1124],"provide":[1126],"less":[1130],"common":[1131],"subgroups":[1132],"lymphoma,":[1136],"\u00c2marginal":[1137],"lymphoma/Waldenstrom's":[1142],"Macroglobulinemia,":[1143],"\u00c2from":[1144],"completed":[1146],"trial":[1149]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2019-11-22T00:00:00"}